Literature DB >> 21688770

Proteomic characterization of influenza H5N1 virus-like particles and their protective immunogenicity.

Jae-Min Song1, Chi-Won Choi, Sang-Oh Kwon, Richard W Compans, Sang-Moo Kang, Seung Il Kim.   

Abstract

Recombinant virus-like particles (VLPs) have been shown to induce protective immunity. Despite their potential significance as promising vaccine candidates, the protein composition of VLPs produced in insect cells has not been well characterized. Here we report a proteomic analysis of influenza VLPs containing hemagglutinin (HA) and matrix M1 proteins from a human isolate of avian influenza H5N1 virus (H5 VLPs) produced in insect cells using the recombinant baculovirus expression system. Comprehensive proteomic analysis of purified H5 VLPs identified viral proteins and 37 additional host-derived proteins, many of which are known to be present in other enveloped viruses. Proteins involved in different cellular structures and functions were found to be present in H5 VLPs including those from the cytoskeleton, translation, chaperone, and metabolism. Immunization with purified H5 VLPs induced protective immunity, which was comparable to the inactivated whole virus containing all viral components. Unpurified H5 VLPs containing excess amounts of noninfluenza soluble proteins also conferred 100% protection against lethal challenge although lower immune responses were induced. These results provide important implications consistent with the idea that VLP production in insect cells may involve similar cellular machinery as other RNA enveloped viruses during synthesis, assembly, trafficking, and budding processes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21688770      PMCID: PMC3151535          DOI: 10.1021/pr200086v

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  60 in total

Review 1.  Recruitment of Hsp70 chaperones: a crucial part of viral survival strategies.

Authors:  M P Mayer
Journal:  Rev Physiol Biochem Pharmacol       Date:  2005       Impact factor: 5.545

2.  Influenza virus-like particles coated onto microneedles can elicit stimulatory effects on Langerhans cells in human skin.

Authors:  Marc Pearton; Sang-Moo Kang; Jae-Min Song; Yeu-Chun Kim; Fu-Shi Quan; Alexander Anstey; Matthew Ivory; Mark R Prausnitz; Richard W Compans; James C Birchall
Journal:  Vaccine       Date:  2010-06-08       Impact factor: 3.641

3.  Virus-like particle vaccine comprised of the HA, NA, and M1 proteins of an avian isolated H5N1 influenza virus induces protective immunity against homologous and heterologous strains in mice.

Authors:  Pan Tao; Mengcheng Luo; Dandan Zhu; Sanfu Qu; Zhenhua Yang; Meng Gao; Deyin Guo; Zishu Pan
Journal:  Viral Immunol       Date:  2009-07       Impact factor: 2.257

4.  Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice.

Authors:  Fu-Shi Quan; Aswani Vunnava; Richard W Compans; Sang-Moo Kang
Journal:  PLoS One       Date:  2010-02-11       Impact factor: 3.240

Review 5.  Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses.

Authors:  Aseem Pandey; Neetu Singh; Suryaprakash Sambhara; Suresh K Mittal
Journal:  Hum Vaccin       Date:  2010-02-24

Review 6.  Influenza vaccines based on virus-like particles.

Authors:  Sang-Moo Kang; Jae-Min Song; Fu-Shi Quan; Richard W Compans
Journal:  Virus Res       Date:  2009-04-15       Impact factor: 3.303

7.  Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets.

Authors:  Amorsolo L Suguitan; Josephine McAuliffe; Kimberly L Mills; Hong Jin; Greg Duke; Bin Lu; Catherine J Luke; Brian Murphy; David E Swayne; George Kemble; Kanta Subbarao
Journal:  PLoS Med       Date:  2006-09       Impact factor: 11.069

8.  Receptors for IgG: subclass specificity of receptors on different mouse cell types and the definition of two distinct receptors on a macrophage cell line.

Authors:  C H Heusser; C L Anderson; H M Grey
Journal:  J Exp Med       Date:  1977-05-01       Impact factor: 14.307

9.  Immunogenicity and protective efficacy of a live attenuated H5N1 vaccine in nonhuman primates.

Authors:  Shufang Fan; Yuwei Gao; Kyoko Shinya; Chris Kafai Li; Yanbing Li; Jianzhong Shi; Yongping Jiang; Yongbing Suo; Tiegang Tong; Gongxun Zhong; Jiasheng Song; Ying Zhang; Guobin Tian; Yuntao Guan; Xiao-Ning Xu; Zhigao Bu; Yoshihiro Kawaoka; Hualan Chen
Journal:  PLoS Pathog       Date:  2009-05-01       Impact factor: 6.823

10.  Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling.

Authors:  Felix Geeraedts; Nadege Goutagny; Veit Hornung; Martina Severa; Aalzen de Haan; Judith Pool; Jan Wilschut; Katherine A Fitzgerald; Anke Huckriede
Journal:  PLoS Pathog       Date:  2008-08-29       Impact factor: 6.823

View more
  14 in total

1.  Complement C3 Plays a Key Role in Inducing Humoral and Cellular Immune Responses to Influenza Virus Strain-Specific Hemagglutinin-Based or Cross-Protective M2 Extracellular Domain-Based Vaccination.

Authors:  Yu-Jin Kim; Ki-Hye Kim; Eun-Ju Ko; Min-Chul Kim; Yu-Na Lee; Yu-Jin Jung; Young-Tae Lee; Young-Man Kwon; Jae-Min Song; Sang-Moo Kang
Journal:  J Virol       Date:  2018-09-26       Impact factor: 5.103

2.  Virus-like particle vaccine protects against H3N2 canine influenza virus in dog.

Authors:  Dong-Hun Lee; Sang-Woo Bae; Jae-Keun Park; Jung-Hoon Kwon; Seong-Su Yuk; Jae-Min Song; Sang-Moo Kang; Yong-Kuk Kwon; Hwi-Yool Kim; Chang-Seon Song
Journal:  Vaccine       Date:  2013-05-22       Impact factor: 3.641

3.  Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection.

Authors:  Min-Chul Kim; Jong-Seok Lee; Young-Man Kwon; Eunju O; Youn-Jeong Lee; Jun-Gu Choi; Bao-Zhong Wang; Richard W Compans; Sang-Moo Kang
Journal:  Antiviral Res       Date:  2013-06-27       Impact factor: 5.970

4.  Roles of antibodies to influenza A virus hemagglutinin, neuraminidase, and M2e in conferring cross protection.

Authors:  Yu-Jin Kim; Eun-Ju Ko; Min-Chul Kim; Yu-Na Lee; Ki-Hye Kim; Yu-Jin Jung; Sang-Moo Kang
Journal:  Biochem Biophys Res Commun       Date:  2017-09-05       Impact factor: 3.575

5.  Engineered Nanoparticle Applications for Recombinant Influenza Vaccines.

Authors:  Zachary R Sia; Matthew S Miller; Jonathan F Lovell
Journal:  Mol Pharm       Date:  2020-08-17       Impact factor: 4.939

6.  Protective CD8 T cell-mediated immunity against influenza A virus infection following influenza virus-like particle vaccination.

Authors:  Emily A Hemann; Sang-Moo Kang; Kevin L Legge
Journal:  J Immunol       Date:  2013-07-24       Impact factor: 5.422

7.  Residual baculovirus in insect cell-derived influenza virus-like particle preparations enhances immunogenicity.

Authors:  Irina Margine; Luis Martinez-Gil; Yi-Ying Chou; Florian Krammer
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

8.  A new bioinformatics approach to natural protein collections: permutation structure contrasts of viral and cellular systems.

Authors:  Daniel J Graham
Journal:  Protein J       Date:  2013-04       Impact factor: 4.000

Review 9.  Systems biology from virus to humans.

Authors:  Youri Lee; Yu-Jin Kim; Yu-Jin Jung; Ki-Hye Kim; Young-Man Kwon; Seung Il Kim; Sang-Moo Kang
Journal:  J Anal Sci Technol       Date:  2015-02-05

10.  One-shot vaccination with an insect cell-derived low-dose influenza A H7 virus-like particle preparation protects mice against H7N9 challenge.

Authors:  Miriam Klausberger; Monika Wilde; Dieter Palmberger; Rong Hai; Randy A Albrecht; Irina Margine; Ariana Hirsh; Adolfo García-Sastre; Reingard Grabherr; Florian Krammer
Journal:  Vaccine       Date:  2013-11-18       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.